AXA Investment Managers’s MoonLake Immunotherapeutics MLTX Stock Holding History

AXA Investment Managers’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$436K	Buy	+60,755	New	+$3.17M	﹤0.01%	1009

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

AXA Investment Managers's MLTX Position: Q3 2025 in Review

AXA Investment Managers opened a new position in MoonLake Immunotherapeutics (MLTX) in Q3 2025: 60,755 shares worth $436K. The stake represents ﹤0.01% of the portfolio and ranks #1009 among its holdings.

134 funds tracked by Wall St. Rank hold MLTX as of Q3 2025.

AXA Investment Managers held 60,755 shares of MoonLake Immunotherapeutics worth $436K as of Q3 2025.
MoonLake Immunotherapeutics was a new AXA Investment Managers position in Q3 2025.
MoonLake Immunotherapeutics made up ﹤0.01% of AXA Investment Managers's portfolio in Q3 2025, its #1009 holding.
134 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2025.

Based on AXA Investment Managers's 13F filing for Q3 2025, filed 14 Nov 2025.